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Abstract Runt-related transcription factor-1 (RUNX1), also known as acute myeloid leukaemia 1 protein (AML1), is a mem-
ber of the core-binding factor family of transcription factors which modulate cell proliferation, differentiation, and
survival in multiple systems. It is a master-regulator transcription factor, which has been implicated in diverse signal-
ling pathways and cellular mechanisms during normal development and disease. RUNX1 is best characterized for its
indispensable role for definitive haematopoiesis and its involvement in haematological malignancies. However, more
recently RUNX1 has been identified as a key regulator of adverse cardiac remodelling following myocardial infarc-
tion. This review discusses the role RUNX1 plays in the heart and highlights its therapeutic potential as a target to
limit the progression of adverse cardiac remodelling and heart failure.
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1. Introduction
The healthcare burden and socioeconomic impact of heart failure is in-
creasing on a global scale leading to significant levels of disability, reduced
quality of life, and mortality.1,2 Adverse changes in the architecture and
function of the heart, collectively referred to as cardiac remodelling, are
critical to the development of heart failure. Adverse cardiac remodelling
occurs in response to many cardiovascular diseases including acute myo-
cardial infarction (MI), hypertension, arrhythmias, and valve disease. For
example, following an MI, adverse cardiac remodelling clinically manifests
as left ventricular (LV) wall thinning, impaired contractility, and dilation;
progression of which is linked to increased deaths or hospitalizations
due to heart failure (Figure 1).3
At the cellular and molecular level, adverse cardiac remodelling
is the result of a complex series of alterations to transcriptional,
structural (e.g. hypertrophy), and electrophysiological signalling
pathways (Figure 1) in cardiomyocytes.4 These changes are accom-
panied by fibroblast proliferation and collagen deposition (fibrosis),
vascular smooth muscle cell proliferation, endothelial dysfunction,
and inflammation.4
Current long-term therapy to prevent or reverse adverse remodelling
remains inadequate and therefore novel strategies to preserve LV func-
tion and limit adverse cardiac remodelling are needed to treat patients
with cardiovascular disease and improve prognosis.5 This review dis-
cusses the structure and function of the master-regulator transcription
factor RUNX1. In particular, we discuss its novel and far-reaching role
within the cardiovascular system, highlighting it as a target of interest for
adverse cardiac remodelling that merits further experimental and clinical
investigation.
2. RUNX1
The RUNX (runt-related) family of genes encode the a-subunits of a
family of transcription factors that orchestrate proliferation, differentia-
tion, and cell survival in multiple lineages. In mammalian species, three a-
subunits exist, known as RUNX1, RUNX2, and RUNX3, each with its
own distinct spatial-temporal and tissue-specific pattern of expression.6,7
All the RUNX proteins partner with a constitutively expressed b subunit
(core-binding factor b; CBFb), to form a transcriptionally active
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heterodimer that can either activate or repress target gene expression.
Although each RUNX protein interacts with the same target consensus
sequence, they display distinct and non-redundant biological functions.7
RUNX1 is best characterized for its role as a key transcriptional regu-
lator of haematopoiesis and its involvement in blood malignancies.8 Mice
with a homozygous knockout of Runx1 lack definitive haematopoiesis
and are unable to survive past an early embryonic stage (days 11.5–12.5)
due to severe haemorrhage within the central nervous system (CNS),
peritoneum, and pericardium.9 In humans, the RUNX1 gene is one of the
most common targets of chromosomal and genetic alterations in acute
leukaemia.10 Whilst the focus of RUNX1 research has therefore
predominately been in the cancer field, accumulating evidence suggests
that RUNX1 has more widespread functions in a range of organs and pa-
thologies than previously considered.
3. RUNX1 structure and regulation
Like the other members of the RUNX family, the RUNX1 protein con-
tains the highly conserved 128 aa region known as the Runt homology
(runt) domain which mediates binding to DNA and facilitates interaction
with CBFb.11 In its free form, RUNX1 has a relatively poor capacity to
Figure 1 Pathological ventricular remodelling. Schematic showing remodelling of the left ventricle (LV) following myocardial infarction (MI). Following MI,
a fibrosous scar forms in the infarcted tissue accompanied by myocyte loss. Adjacent to the infarcted tissue in the region bordering the remote LV, the bor-
der-zone region, myocytes thicken and elongate and excitation–contraction coupling becomes impaired. In terms of gross architecture of the LV, the early
phase of remodelling is characterized by thinning and elongation of the infarcted zone followed by ventricular dilation, where the LV transitions from an ellip-
tical shape to a spherical shape. Schematic was prepared using Servier Medical Art by Servier under a Creative Commons Attribution 3.0 Unported License.
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..bind DNA due to negative regulation from regions at the N- and C-ter-
minal limits of the Runx domain.12,13 On binding to CBFb, structural
rearrangements of the runt domain take place which unmask and stabi-
lize the DNA-binding site resulting in a markedly increased affinity for
DNA.12,14 Moreover, whilst the RUNX1 protein itself has a short half-
life of approximately 60 min, formation of the RUNX1–CBFb hetero-
dimer protects RUNX1 from degradation by the ubiquitin ligase com-
plex, increasing its half-life three-fold.15 Transcriptional ability is further
modulated via protein-interacting domains within the RUNX1 C-termi-
nus including the PY motif (proline-rich peptide that interacts with pro-
teins with a WW domain), and the VWRPY motif [which acts as a
docking site for the assembly of the Groucho/Transducin-like enhancer
of split (TLE) family of co-repressor proteins].16,17 Via these domains,
RUNX1 can form a platform for the assembly of other transcription fac-
tors, co-activators, and chromatin modulators to form large transcrip-
tional complexes16 (Figure 2A). It is likely that the particular combination
of mediators recruited to these complexes dictate the profile of the
genes targeted and whether they are activated or repressed, leading to
both indirect regulation and context-dependent function.16
Expression of RUNX1 itself is tightly controlled at the transcriptional,
translational, and post-translational level, which also contributes to the
strong context specificity of RUNX1 function. The RUNX1 gene is under
the control of a dual promoter system comprising a distal P1 and a proxi-
mal P2 promotor and alternative usage of these promoters leads to the
generation of mRNA isoforms that differ in their 50-untranslated region
(UTR) and N-terminal coding sequences18,19 (Figure 2B, C). The biologi-
cal significance of the dual promoter system has not been fully eluci-
dated; however, their differential expression during developmental
haematopoiesis appears important for cell specification.20 Expression of
the P2 transcript predominates during haematopoietic stem and progen-
itor cell (HSC) emergence from the haemogenic endothelium during
embryonic development, whereas P1 transcript expression increases as
HSCs colonize the liver and becomes the dominant isoform in both liver
HSCs and in adult HSCs in the bone marrow.20,21 The differing lengths
of the 50-UTR of the P1 and P2 transcripts may also facilitate their differ-
ential expression in distinct cellular contexts by influencing their transla-
tion efficiency. The human RUNX1 P1 transcript has a 50UTR that is 452
base pairs (bp) in length and is translated efficiently; however, the 50-
UTR of the P2 transcript is substantially longer at 1631 bp and forms a
secondary structure which appears to hinder its translation in vitro.22
Whilst the P1-50-UTR is translated by a cap-dependent mechanism (the
most common means of translation direction under basal conditions),
translation of P2 transcripts is directed by the presence of an internal ri-
bosomal entry site (IRES), which recruits the ribosome to directly initiate
translation thus allowing the canonical, cap-dependent mode of transla-
tion initiation to be bypassed.22 IRES-mediated translation has been sug-
gested to predominate under conditions of stress, such as hypoxia or
apoptosis when cap-dependent translation is diminished.23 Messenger
RNA isoforms with different translational regulation may allow a shift
from the predominant expressed RUNX1 protein isoform and may tai-
lor RUNX function as part of an adaptive response to stress.7
Further diversity in the RUNX1 gene products is augmented by splic-
ing and exon skipping of the P1 and P2 transcripts to yield further iso-
forms with different functions and expression patterns.7,18 For example,
in humans, P1-driven transcription produces the RUNX1c isoform,
whereas P2 activity yields the RUNX1a and RUNX1b isoforms.18 This
gives rise to a range of protein isoforms, ranging in size from 20 to
52 kDa18,24 (Figure 2D). RUNX1a is truncated at exon 7 and so has
DNA-binding capacity but lacks the C-terminal transcriptional regulatory
domain seen in RUNX1b and RUNX1c. It has therefore been suggested
that RUNX1a may act as an antagonist to transcriptional activation
driven by RUNX1b and RUNX1c.18,24 Indeed, in a murine myeloid cell
line, ectopic expression of AML1a (RUNX1a) only or a combination of
AML1a and AML1b (RUNX1b) was found to have an opposing effect on
the response of the cells to granulocyte colony-stimulating factor (G-
CSF). Overexpression of AML1a alone was found to block granulocytic
differentiation induced by G-CSF, whereas additional expression of
AML1b was found to rescue granulocytic differentiation.25
Additional control over RUNX1 stability and function is achieved by a
range of post-translational mechanisms including phosphorylation, acety-
lation, and ubiquitination (Figure 3). Acting as scaffolds for multiple pro-
tein complexes the outcome of RUNX binding to DNA is heavily
influenced by interaction with different activating or repressive co-
factors. Post-translational modifications can influence RUNX1 activity,
affinity for DNA, and its stability at least in part by directing its binding to
other co-factors and in this way provides a means to fine-tune RUNX1
activity in response to external stimuli or cellular events.26 For example,
phosphorylation was shown to enhance the transactivation activity of
RUNX1.27 Subsequently, phosphorylation has been shown to reduce in-
teraction with histone deacetylases28 and other repressors such as
sin3a.29 Conversely, phosphorylation (albeit on specific residues) has
also been shown to reduce activity.30 RUNX1 can be phosphorylated in
response to cytokine/growth factor-induced signalling, underlining how
transcription factor activity can be modulated by external factors.30
Given the importance of post-translational modifications it is not surpris-
ing that aberrant phosphorylation of RUNX1 has been linked to disease.
FMS-like tyrosine kinase 3 (FLT3) mutations resulting in constitutive acti-
vation are common in AML and have been correlated with high levels of
RUNX1. A study by Behrens et al.31 revealed that constitutive FLT3 acti-
vation was associated with phosphorylation of RUNX1 residues in the
inhibitory domain of RUNX1, resulting in increased expression of down-
stream oncogenic targets. Thus, it is possible that FLT3 activation may
recruit RUNX1 as its oncogenic partner at least in part through modify-
ing its activity.
Other modifications to RUNX1 affect its interaction with regulatory
co-factors, for example, methylation can affect RUNX1 partner interac-
tions to both promote32 and repress33 transcriptional activity. Similarly,
p300-mediated acetylation of RUNX1 has been associated with in-
creased DNA binding and transcriptional activity.34 Ubiquitination fre-
quently marks proteins, including RUNX1, for degradation by the
proteasome but its effects can be more subtle and, in some cases, can re-
sult in protein stabilization.35
The highly complex regulation of RUNX1 expression is perhaps re-
flective of a need to tightly control and direct the cellular processes of
cellular differentiation, proliferation, and lineage commitment in which
RUNX1 is critical. Consequently, dysregulation or altered expression of
RUNX1, which is well documented in cancer patients, leads to disrupted
cellular function and disease.10
4. RUNX1 in the developing heart
In the developing embryo, RUNX1 is the most broadly expressed of all
the RUNX proteins and is expressed in a range of tissues including the
mesenchymal tissue of the heart and in vascular tissue.6 The importance
of RUNX1 in the development of the vasculature is highlighted in the
1412 A. Riddell et al.
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lack of definitive haematopoiesis and abnormal vasculature development
in many organs.9 In the heart, these mice have an underdeveloped coro-
nary plexus and smaller ventricular free wall vessels.36 This coincides
with changes in heart structure including ventricular septal defects and
the development of thin myocardium. In ex vivo preparations of
explanted ventricle from embryonic stage 11.5, Runx1 null preparations
showed less endothelial sprouting.36 The effects on the developing
Figure 2 RUNX1 structure and regulation. Illustration of RUNX1 transcriptional regulatory complexes for activation and repression of gene expression
(A). Schematic depicting RUNX1 gene structure (B). Expression of RUNX1 is initiated by two promoters: distal P1 and proximal P2. (C) Alternative pro-
moters and gene-splicing results in different 50-UTRs. The P1-50-UTR contains four exons and the P2-50-UTR has a single exon and an internal ribosome en-
try site (IRES). This results in three major isoforms of RUNX1; 1A and 1B transcribed from P2 and isoform 1C transcribed from P1. (D) Schematic of the
proteins encoded by the RUNX1 isoforms with the major functional domains marked: runt-homology domain (RHD) and transactivation domain (TAD).
Figure prepared using information from various sources.186–188
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vasculature may be linked to a haematopoietic function; however, a con-
tributing non-haemogenic role of RUNX1, perhaps directly affecting ves-
sel and heart structure cannot be ruled out based on this study
alone.36,37
Expression of RUNX1 in the neonatal heart is higher compared with
adult heart tissue.38 Although the reasons for this are unexplored, it is in-
teresting to note that genes with RUNX1-binding sites within their pro-
moter region are overrepresented in the collection of genes that
become methylated during the first week of life.39 Promoter methylation
is an epigenetic modification which usually leads to gene silencing by
blocking the access of transcriptional machinery.40 In this setting, in-
creased gene methylation may be important in the maturation process
by switching off genes necessary for heart development to support tran-
sition to a more adult phenotype.39 Of note, methylation of RUNX1 tar-
get genes during the 7 days after birth coincides with a loss of the hearts
proliferative and regenerative capacity.39 This is an intriguing finding given
the fact that there is a known link between RUNX1 and the transcrip-
tional co-activators Yap (Yes-associated protein) and TAZ (transcrip-
tional co-activator with PDZ binding motif), which have a regenerative
role in the neonatal and adult heart.41–43
As RUNX1 has been shown to be involved in female sex development
and is a mediator of female hormone signalling, with RUNX1 dysregula-
tion involved in breast, ovarian, and uterine cancers,44,45 it is important
to consider that RUNX1 may have differing roles within the female vs.
male cardiovascular system.
5. RUNX1 expression in cardiac
injury
Although expression of RUNX1 in the adult heart is reported to be low,
several studies have demonstrated that RUNX1 is increased in the con-
text of cardiac pathology.46–49 This was first demonstrated by
Gattenlohner et al.48 in 2003 using human heart tissue autopsies from
patients with diagnosed ischaemic cardiomyopathy. Up-regulation of
RUNX1 mRNA in the ischaemic tissue was accompanied by
overexpression of the 52 kDa RUNX1 isoform and down-regulation of a
38 kDa isoform predicted to be the RUNX1 AML-1 delta N isoform
which has a known dominant-negative function.48,50 In a separate study,
RUNX1 was also up-regulated in heart tissue from patients with chronic
dilated cardiomyopathy compared with control myocardium.47 These
findings have been reinforced by rodent models of MI which have shown
induction of RUNX1 in the nuclei of cardiomyocytes within the myocar-
dial region bordering the infarcted tissue (border zone) as early as 24 h
post-MI.46,47 Whilst in the early stages after MI the up-regulation of
RUNX1 seems specific to the border zone, by 8 weeks post-injury
Runx1 mRNA appears up-regulated in the LV remote from the infarct.46
Interestingly, cardiac up-regulation of RUNX1 does not appear to be
specific to ischaemic pathology as RUNX1 was also found to be in-
creased experimentally in animal models of: (i) diabetic cardiomyopathy;
(ii) pressure overload; and (iii) dilated cardiomyopathy.51–53 More re-
cently, RUNX1 has been shown to be involved in zebrafish heart regen-
eration following cardiac injury.54 Cryo-injury resulted in increased
RUNX1 expression within various cell types of the myocardium includ-
ing cardiomyocytes, myofibroblasts, endocardial/endothelial, epicardial,
and thrombocytes, where it inhibits heart repair.
6. Triggers of RUNX1 expression
Up-regulation of RUNX1 in damaged tissue is reported in non-cardiac
tissues including the CNS, lungs, and skeletal muscle.55–58 In the nervous
system, RUNX1 is up-regulated in response to sciatic nerve crush injury
and controlled cortical impact injury.56,59 Comparable with observations
made in the heart where RUNX1 was found to be increased in the
infarct border zone at 24 h post-MI,46 Logan et al.56 also identified in-
creased RUNX1 expression at the injury site as early as 1-day post-corti-
cal injury. RUNX1 induction at early time points in a range of tissues
following different insults may indicate that RUNX1 is up-regulated as
part of a common response to injury independent of the precise nature
of the original insult.56 An interesting comparison can be made between
RUNX1 expression in cardiac and skeletal myocytes. Like heart tissue,
RUNX1 is increased in skeletal myocytes in a range of pathologies in-
cluding ischaemic muscle, cardiotoxin treated muscle, and mouse mod-
els of Duchenne musclar dystrophy and amylotrophic lateral
sclerosis.57,60,61 Denervation of skeletal muscle is associated with a rapid
and marked induction in RUNX1 expression; for example, in rat
hindlimb muscle a two-fold induction of Runx1 mRNA was detected at
1-day post-denervation, rising to 50- to 100-fold by day 5 post-denerva-
tion.58,62 Significantly, the up-regulation of RUNX1 in response to dener-
vation can be attenuated by the daily application of either electrical
stimulation or stretch to the denervated muscle.63 RUNX1 expression is
increased in aged muscle alongside denervation and sarcopenia and can
similarly be reduced by physical intervention. In a small number of older
obese men and women and in aged female mice with sarcopenia resis-
tance training, which is known to preserve the neuromuscular junction
and improve innervation,64 was found to reduce RUNX1 expres-
sion.65,66 Interestingly, in skeletal muscle and in ischaemic cardiomyopa-
thy RUNX1 up-regulation coincides with the up-regulation of the neural
cell adhesion molecule (NCAM, CD56).48 Whereas, NCAM up-regula-
tion in rhabdomyosarcoma occurred where myocytes were separated
by infiltrating tumour, NCAM up-regulation in ischaemic heart tissue
arose where cardiomyocytes were separated by scar tissue. If NCAM
expression is up-regulated downstream of RUNX1 this may suggest that
Figure 3 Post-translational modifications of human RUNX1.
Schematic depicting post-translational modifications of RUNX1b. Runt-
homology domain (RHD) is the DNA- and CBFb-binding domain.
Transactivation domain (TAD) is important for transcriptional activa-
tion. Numbers refer to amino acid residues from N terminus. Ac, acety-
lation; APC, anaphase-promoting complex; K, lysine; Me, methylation;
P, phosphorylation; R, arginine; S, serine; SCF, Skp1/Cullin/F-box pro-
tein complex; T, threonine; Ub, ubiquitination; Y, tyrosine. Figure pre-
pared using information from various sources.189,190
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physical disruption of cell–cell contact or adhesion may contribute to
RUNX1 regulation,48 possibly by affecting cell communication.
Changes in RUNX1 expression in response to alterations in electrical
activity, cell–cell communication or as a result of physical strain or ten-
sion may explain why RUNX1 up-regulation is first observed in the bor-
der zone following MI. After MI, cardiomyocytes within the border zone
exhibit abnormal cell–cell communication due to altered gap-junction
distribution and physical disruption of cell contact by interstitial fibrosis
and necrotic myocytes, leading to electrical heterogeneity and the pre-
cipitation of arrhythmias.67 The MI border zone is also subjected to high
physical stress and abnormal stretch created at the boundaries between
viable cardiomyocytes alongside dead cells and non-contractile scar tis-
sue.68–70 As the heart attempts to compensate for the hypocontractile
infarct, the remote myocardium also becomes subject to abnormal wall
stress which may lead to the up-regulation of RUNX1 in this region at a
later stage post-MI.71
The apposition of the border zone alongside the infarct means that vi-
able border zone cardiomyocytes are also directly exposed to the in-
flammatory milieu of the infarcted tissue.72 Post-infarction, there is a
rapid immune response to cellular damage, resulting in the release of
damage signals, chemokines, and cytokines and the recruitment of leuco-
cytes into the damaged area.73 Consequently, there is an intense surge
of immune signals which could act as a local trigger for RUNX1 expres-
sion. Oncostatin-M, which is a member of the IL-6 cytokine family and is
secreted by inflammatory cells in response to injury,74,75 has already
been identified as a potent inducer of RUNX1 in cultured cardiomyo-
cytes.47,51 In addition, transgenic mice with a heart-specific overexpres-
sion of monocyte chemotactic protein-1 (MCP-1) exhibit pathological
macrophage infiltration in the myocardium, which occurs alongside en-
hanced oncostatin-M and RUNX1 expression, providing evidence that
an association between inflammation, oncostatin-M, and RUNX1 up-
regulation may exist.47,76 Other inflammatory mediators with known
links to RUNX1 include the pro-inflammatory cytokine IL-1b and the
transcription factor TGF-b. Treatment of a human glioblastoma cell line
with IL-1b was shown to up-regulate RUNX1 expression via the p38
MAPK cascade77 and TGF-b has been shown to increase RUNX1 ex-
pression in a range of cell types including adult hippocampal precursor
cells,78 mesenchymal stem cells, CD4 T cells, and a mouse hepatocyte
cell line.79,80 Currently, the effects of these inflammatory mediators on
RUNX1 expression in the myocardium remain unknown.
7. RUNX1 and adverse cardiac
remodelling
Work conducted using mice with an inducible cardiomyocyte-specific
Runx1 deficiency was the first to provide evidence that the up-regulation
of RUNX1 post-MI drives adverse cardiac remodelling.46 At baseline,
Runx1-deficient mice had equivalent echocardiographic contractile
parameters to their littermate controls. However, following MI stark dif-
ferences in contractile function and myocardial remodelling emerged.
Whilst classic adverse cardiac remodelling occurred in control mice
post-MI including declining systolic function, thinning of the left ventricu-
lar free wall, and dilation of the left ventricular chamber, the same param-
eters were remarkably absent in Runx1-deficient mice.46 At 8 weeks
post-MI, control mice had developed eccentric hypertrophy, character-
ized by cardiomyocyte elongation and thinning. In contrast, this was no-
tably undetectable in the Runx1-deficient mice. The link between
RUNX1 and adverse cardiac remodelling has now been corroborated
by others in mice81 and also in cryo-injured zebrafish hearts, where
Runx1 knockout prevented adverse cardiac remodelling by promoting
faster scar degradation.54 The cellular composition of the scar was differ-
entially regulated so that smooth muscle and collagen gene expression
was significantly reduced, subsequently reducing the amount of collagen,
and fibrin deposition. Myofibroblast formation was also reduced whilst fi-
brinolysis increased, thus allowing invasion of proliferative cardiomyo-
cytes and hence enhancing muscle regeneration.54
The improvement in function and myocardial architecture of mouse
hearts with Runx1-deficiency post-MI may be explained by an effect of
RUNX1 on calcium homeostasis in cardiomyocytes. At 2 weeks post-MI,
cardiomyocytes isolated from Runx1-deficient hearts had increased am-
plitude of electrically stimulated sarcoplasmic reticulum (SR)-mediated
Ca2þ release, a faster rate of calcium removal from the cytosol by the SR
Ca2þ-ATPase (SERCA) and a higher SR content.46 Although the abso-
lute protein levels of the endogenous SERCA inhibitor phospholamban
(PLN) were similar between Runx1-deficient and control cardiomyo-
cytes, the proportion of PLN phosphorylated on Ser16 and Thr17 resi-
dues was increased in Runx1-deficient cardiomyocytes. This was
accompanied by a parallel decrease in protein phosphatase 1, the phos-
phatase responsible for the dephosphorylation of PLN.46 In its phos-
phorylated state, the inhibitory actions of PLN on SERCA is relieved,
allowing enhanced Ca2þ uptake into the SR which lowers end-diastolic
cytosolic Ca2þ concentration and improves the relaxation of the heart
during diastole.82,83 SR Ca2þ content is also increased, leading to aug-
mented release of Ca2þ with each electrically stimulated transient and
therefore improved contraction.84,85
The insights offered by McCarroll et al., into the protection afforded
by Runx1-deficiency fit with other studies in the field where improve-
ments in cardiomyocyte calcium handling can have a profound beneficial
effect on cardiac structure and function.84,86,87 Interestingly, the im-
proved contractility noted in Runx1-deficient mice occurred in the ab-
sence of an effect on infarct size, another key determinant of systolic
function after MI.46 This finding additionally implies that the protective in-
fluence of Runx1-deficiency likely relates to the ability of viable cardio-
myocytes to functionally compensate for cardiomyocyte death via
preserving calcium handling rather than a direct effect of Runx1-defi-
ciency on the salvage of ischaemic cardiomyocytes. Importantly and in
agreement with mouse studies, several calcium-dependent genes were
up-regulated in Runx1 knockout zebrafish hearts.54
Thus far, the direct mechanisms linking RUNX1 to changes in cardio-
myocyte Ca2þ handling are unknown and require further study. Given
the preponderance of Ca2þ dysregulation across cardiac pathologies, in-
cluding diabetic and hypertensive heart disease,88,89 and its contribution
to heart failure progression,90 it will be useful to establish whether ma-
nipulation of RUNX1 in other cardiac disease contexts improve cardiac
function.
8. Interaction of RUNX1 with
signalling pathways involved in
cardioprotection and adverse
cardiac remodelling
Improved Ca2þ homeostasis may not be the exclusive mechanism un-
derlying protective influence of RUNX1 deficiency on the heart. As a
master transcription factor, RUNX1 has the potential to simultaneously
influence several downstream signalling pathways which may also dictate
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cardiomyocyte phenotype and the global response of the heart to injury.
Although the direct targets of RUNX1 in the heart have not been eluci-
dated, RUNX1 has been demonstrated to interact with signalling path-
ways in other tissues that are implicated in cardioprotection and adverse
cardiac remodelling.
RUNX1 is known to interact with signalling mediated by hypoxia-in-
ducible factor 1-alpha (HIF-1a).91 HIF-1a belongs to the HIF family of
transcription factors which are key orchestrators of the cellular re-
sponse to ischaemia.92 Many studies have demonstrated that augmented
HIF-1a signalling is protective in the context of MI and leads to improved
heart contractility, angiogenesis and reduced infarct size93,94; how
ever, chronic activation of HIF-1a signalling in the long term may
exacerbate adverse cardiac remodelling and advance progression to
heart failure.95–97 In haematopoietic cells with forced expression of
RUNX1 and HIF-1a, RUNX1 has been shown to physically interact with
HIF-1a and reduce transcription of HIF-1a targets including vascular en-
dothelial growth factor (VEGF) and glucose transporter 1 (GLUT 1).
Conversely, forced expression of HIF-1a was found to enhance
RUNX1-mediated transcription.98 In a separate study, RUNX1 overex-
pression in a glioblastoma cell line down-regulated genes involved in the
hypoxic response including the known HIF-1a targets hexokinase 2 (HK
2), caveolin 1 (CAV1), adenosine A2B receptor, and protein phospha-
tase 1 regulatory subunit 3C gene (PPP1R3C).99–101 RUNX1 itself may
be up-regulated by HIF-1a, as chemical stabilizers of HIF-1a including
dimethyloxalylglycine (DMOG) and cobalt chloride (CoCl2) have been
shown to increase RUNX1 expression102–104 and a correlation between
RUNX1 and HIF-1a transcripts was identified in hippocampal transcrip-
tomic data from in-bred mouse strains.78 Whether RUNX1 interacts
with HIF-1a in the heart has not been elucidated.
TGF-b-mediated signalling is also linked to RUNX1 and implicated in
cardiac remodelling. RUNX1 expression is activated by TGF-b and sev-
eral of the biological effects of TGF-b stimulation have been shown to in-
volve RUNX1 including myofibroblast differentiation and
fibrosis.78,105,106 RUNX1 can direct TGF-b signalling through physical
interactions with SMAD proteins, the intracellular transducers of TGF-b
receptor activation.78,107 Shortly after MI, TGF-b activation is considered
protective and fundamental for infarct healing108; however, prolonged
and excessive TGF-b signalling promotes adverse cardiac remodelling in-
cluding interstitial fibrosis and hypertrophy.108,109 Work is needed to de-
termine whether RUNX1 is linked to TGF-b signalling in the heart and
whether this interaction is involved in cardiac pathology.
Another means by which RUNX1 can alter cellular function and re-
sponse to injury is via interaction with microRNAs (miRNAs). miRNAs
are small non-coding RNAs which post-transcriptionally modify gene ex-
pression by interacting with the 30UTR of target mRNAs. As
microRNAs can target hundreds of mRNA sequences and thus simulta-
neously affect several targets within the one pathway, small changes in
their expression has the potential to amount to a significant biological ef-
fect.110,111 ChIP-seq data from studies in haematopoietic cells have
shown that RUNX1 physically binds over 200 miRNA genes suggesting a
potential for RUNX1 to influence a remarkable number of miRNA net-
works.112 An increasing number of studies are providing experimental
support for this observation and as a result, the number of validated
RUNX1 miRNA targets reported is continuously increasing, including
the identification of RUNX1 miRNA targets which have known links to
cardiovascular disease.113,114 For example, miR-24 which is down-regu-
lated by RUNX1, decreases in the ischaemic border zone after
experimental MI.114–117 Moreover, miR-24 appears to have a cardiopro-
tective role within this setting, as local delivery of miR-24 into the border
zone after infarction reduced cardiomyocyte apoptosis, decreased in-
farct size, and improved cardiac contractility.115 It is possible that
RUNX1 may contribute to reduced miR-24 in the aftermath of MI, and
in doing so may adversely affect the cardiac outcome; however, this is
yet to be investigated.
The miR-17-92 cluster is a further example of a group of miRNAs that
are linked to both RUNX1 and cardiac pathology. The miRNAs in this
cluster target the 30UTR of RUNX1 to down-regulate its protein ex-
pression and are also themselves targeted by RUNX1 as part of a nega-
tive feedback loop.117,118 Of note, the miR-17-92 cluster has been
associated with cardiomyocyte differentiation and proliferation, and fur-
thermore, in a mouse model of MI, miR-17-92 overexpression in cardio-
myocytes was reported to improve cardiac function and increase the
number of proliferating cardiomyocytes within the infarct border
zone.118,119
9. RUNX1 targets in skeletal muscle
An interesting comparison can be made between the role of RUNX1 in
skeletal and cardiac muscle post-injury and may shed light on potential
RUNX1 targets in the heart. Both skeletal and cardiac myocytes have a
primary contractile function and are thus equipped with highly organized
arrangements of myofilaments and complex calcium signalling mecha-
nisms to facilitate this.120 Notably, both cell types respond to a range of
insults via the up-regulation of RUNX1.120 However, in denervated skel-
etal muscle inactivation of RUNX1 by mutation severely affects the re-
sponse of muscle fibres to denervation, leading to worsened fibre
atrophy, excessive autophagy and structural abnormalities including mis-
alignment and fragmentation of the z discs, dilation of the SR, and an al-
tered myofilament composition.62 Thus, in skeletal muscle fibres,
RUNX1 appears to protect the structural and functional integrity of skel-
etal muscle fibres in the face of injury or insult. This contrasts with its
role in the heart post-MI, where RUNX1 appears to reduce cardiomyo-
cyte function and promotes adverse cardiac remodelling. The differences
between RUNX1 function in cardiac and skeletal muscle are fascinating
yet are not easy to reconcile. They perhaps stem from the highly context
dependency of RUNX1 function and may arise either because RUNX1
affects distinct processes in the two cell types or may exist because
RUNX1 has opposing effects on the same target pathways. Interestingly,
several of the 29 genes found to be dysregulated in RUNX1 mutated de-
nervated skeletal muscle have previously been linked to cardiac contrac-
tility and cardiac remodelling. For example, RUNX1 was found to
maintain or induce the expression of osteopontin, PLN, thrombospon-
din 1 in the face of denervation.62,121,122 Following MI, osteopontin up-
regulation in cardiomyocytes has been found to negatively correlate
with left and right ventricular ejection fraction and positively correlate
with cardiomyocyte hypertrophy.123 In contrast, thrombospondin 1 up-
regulation in the extracellular matrix post-MI appears beneficial by pre-
venting excessive infiltration of macrophages and myofibroblasts into the
peri-infarct zone.124 Further investigation is now necessary to explore
whether RUNX1 acts on similar targets in cardiac muscle and to under-
stand the consequence of these RUNX1 interactions in the context of
cardiac disease.
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10. RUNX1 in differentiation and
proliferation
The role of RUNX1 in proliferation and differentiation is well docu-
mented. In tissues such as the skin, intestine, mammary gland, and in the
haematopoietic system RUNX1 participates in the regulation of stem
cell quiescence by directing entry and exit from the cell cycle.125,126 In
general, RUNX1 appears to support or maintain proliferation, in part by
promoting G1 to S progression through the cell cycle.126–128 The con-
trol of proliferation appears intimately linked with cellular differentiation,
the balance of which may depend on the level RUNX1 expression.
Inhibition of RUNX1 in mouse neurosphere cultures with the inhibitor
Ro5-3335, a benzodiazepine which may reduce RUNX1 activity by dis-
rupting RUNX1–CBFb interactions129 was shown to inhibit proliferation
of neural stem or progenitor cell populations without affecting cell viabil-
ity or differentiation.130 In contrast, lentiviral-mediated RUNX1 overex-
pression did not affect the proliferative capacity of the cells but instead
up-regulated markers of neuronal differentiation and the development
of a neuronal-like morphology.130
In the heart, RUNX1 may be similarly linked to cell differentiation.
This may become important after cardiac injury because the cellular dif-
ferentiation status of cardiomyocytes in the injured or stressed myocar-
dium131 is believed to be closely linked to the remodelling that takes
place. Cardiomyocyte dedifferentiation, a phenotype characterized by
the loss of the mature sarcomeric structure and the activation of a foetal
gene expression profile, occurs in response to injury and has been
reported in the ischaemic heart and the MI border zone, in dilated car-
diomyopathy, and the pressure overloaded heart.47,51,52,131–133 Cells
with a dedifferentiated phenotype also stain positive for RUNX1; how-
ever, whether up-regulation of RUNX1 plays a direct role in orchestrat-
ing dedifferentiation in the heart has not been explored.47,51 Of note, in
one study which looked at the ability of adult murine cardiomyocytes to
dedifferentiate in an in vitro co-culture model with neonatal rat ventricu-
lar cardiomyocytes, dedifferentiation, and proliferation of the adult cardi-
omyocytes coincided with an increase in RUNX1 expression, which was
lost when the cardiomyocytes re-differentiated.132 Cardiomyocyte de-
differentiation may confer stress resistance to hypoxic conditions and/or
metabolic strain which may allow performance to be sustained during
pathophysiological stress, providing the damage imposed on the myocar-
dium is self-limiting in nature.131 However, in the long term, chronic ex-
pression of foetal genes involved in metabolism, calcium homeostasis,
and contractility may lead to mitochondrial dysfunction, impaired con-
tractility contributing to adverse cardiac remodelling, and thus promote
progression to heart failure.76,134 Improved understanding of the tran-
scription factors driving cardiomyocyte dedifferentiation in response to
injury may therefore be a crucial step towards the development of thera-
pies which attenuate adverse cardiac remodelling.
Transcription factors that regulate the balance between proliferation
and differentiation are also of interest because of the centrality of these
processes to tissue repair and regeneration. In many tissues, resident
stem or progenitor cells can proliferate and differentiate to replace in-
jured cells.135 RUNX1 has already been identified as a key regulator of
stem cell behaviour in the haematopoietic system, skeletal muscle, hair
follicles, and the nervous system.125,126,136 RUNX1 appears to have a
role in skeletal muscle regeneration in mice that have lost skeletal muscle
dystrophin function (mdx mice).137
In the absence of dystrophin, the mice repeatedly undergo cycles of
myonecrosis followed by regeneration which preserves muscle mass.
However, when the mdx mice were developed to have a skeletal muscle
Runx1-deficiency in addition to the loss of dystrophin, muscle mass was
not maintained beyond 2 weeks, suggesting impaired regeneration of
muscle fibres.137 The Runx1-deficient mdx mice were found to have se-
vere muscle deterioration and fibrosis, accompanied by an impaired ex-
ercise capacity and reduced evidence of regenerative fibres. In the same
study, primary myoblasts with a RUNX1 deficiency showed reduced
proliferation, G1 arrest and premature differentiation whereas, ectopic
expression of RUNX1 in myoblasts was found to reduce differentia-
tion.137 RUNX1 may facilitate regeneration in this context by preventing
premature differentiation of proliferating myoblasts until enough cells
have accumulated to permit effective repair.
In contrast to skeletal muscle, the heart has a very limited capacity to
regenerate and this is evidenced by the permanent damage to the myo-
cardium caused by infarction.138,139 Although there is evidence suggest-
ing that cardiomyocytes can proliferate, the rate of renewal is very low,
estimated at 0.5–2% of cardiomyocytes each year.140,141 Cardiomyocyte
proliferation may increase following injury; however, any contributions
to tissue repair are considered small.140,142 This contrasts with findings in
the neonatal mouse heart as well as zebrafish and newts where a robust
proliferative regenerative response is mounted following cardiac resec-
tion.143–145 Understanding the developmental mechanisms of cardio-
myocyte proliferation and regeneration and how these are altered in the
adult heart may therefore be a crucial step towards the identification of
reparative pathways that could be harnessed to improve cardiac regen-
eration in the future.146 Indeed, a recent study has provided promising
evidence that stimulation of endogenous cardiomyocyte proliferation
programmes in large mammals is a valid approach to facilitate cardiac re-
pair by increasing myocardial mass and contractility after MI.147
Whilst RUNX1 has been identified to be a key player in zebrafish
heart regeneration following cardiac injury54 its role in cardiomyocyte
proliferation programmes in mammals remains unknown. Investigation
of this gap in our knowledge is warranted given that RUNX1 regulates
proliferation, differentiation, and tissue regeneration in other settings.
RUNX1 has also been shown to interact with the Hippo pathway, a
key pathway linked to cardiac regeneration in neonatal as well as adult
hearts.148,149 Like RUNX1, the Hippo pathway and its downstream
effectors YAP and TAZ are involved in proliferation, differentiation, and
expansion of stem cell populations.150 Adult mice with a heterozygous
deletion of YAP show increased scarring and depressed cardiac contrac-
tility following MI and conversely, experimental induction of YAP in car-
diomyocytes post-MI has the opposite effect.151,152 RUNX1 has been
shown to interact via its PY motif to YAP WW domain to co-regulate
target genes.43,153 Co-expression of RUNX1 and YAP leads to the re-
pression of the YAP gene signature and a functional attenuation of the
effects of YAP activation in mammary epithelial cell lines.43 Although lit-
tle is known about the interaction of YAP and RUNX1 in the heart, it is
interesting to note that oncostatin-M, a potent inducer of RUNX1, is ac-
tivated downstream of YAP in cardiomyocytes, suggesting that an indi-
rect link between RUNX1 and YAP may exist within the heart.52
11. RUNX1 in non-myocytes
Whilst studies have focused on the function of RUNX1 within cardio-
myocytes to date, a role for RUNX1 in other non-cardiomyocyte cells
types may also exist. Other cell types within the myocardium include
fibroblasts, endothelial cells, resident immune cells, and neural cells, each
with their own role in cardiac physiology and disease. Interestingly,
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increased Runx1 mRNA expression is reported in non-cardiomyocyte
cells following MI, with 14% of non-cardiomyocytes within the infarct
zone expressing RUNX1 at day 1 post-MI and up to 26% and 35% of
non-cardiomyocytes expressing RUNX1 within the infarct zone and
border zone, respectively, by 2 weeks post-MI.46 Similarly, in a mouse
model of DCM, RUNX1 expression was increased 4.8-fold in DCM
non-myocytes compared to non-myocytes in control hearts.53 The ex-
act non-myocyte cell types in which RUNX1 is up-regulated is unknown,
and whether this affects cardiac remodelling remains unexplored.
However, in a recent study which employed a combination of computa-
tional transcription factor-binding analysis and RNA-seq data, the
RUNX1 binding motif was identified as a main motif in cardiac fibroblast-
specific active enhancers. This suggests that RUNX1 may have an impor-
tant role in cardiac fibroblasts.154 Certainly, RUNX1 has been shown
to regulate proliferation in stromal fibroblasts from human
prostate-derived mesenchymal stem cells and is involved in the activa-
tion of fibroblasts to myofibroblasts.105 As the activation and prolifera-
tion of fibroblasts in the heart after injury is an integral part of the cardiac
repair process and yet in the longer term contributes to cardiac pathol-
ogy, it will be interesting to see if RUNX1 is implicated within this pro-
cess in the future.155
Many studies document a role for RUNX1 in the development, polari-
zation, and function of the mammalian immune system. A full discussion
of RUNX1 in inflammation and immunity is beyond the remit of this re-
view and can be found elsewhere.156–158 However, it is important to
consider that the ability of RUNX1 to modulate the inflammatory phe-
notype in response to damage may have profound implications in the in-
jured heart, where immune cell function impacts upon remodelling and
repair.159,160 Generally, a loss of RUNX1 function is associated with
heightened inflammatory responses.161–163 Mice with a Runx1 deletion in
alveolar epithelial cells had up-regulated NF-jB signalling, augmented
pulmonary inflammation and an earlier onset of death after pulmonary
LPS exposure.55 Further studies have suggested that RUNX1 attenuates
NF-jB signalling by directly binding IjB kinase (IKK) in the cytoplasm and
preventing it from targeting IjBa, an endogenous inhibitor of NF-jB, for
degradation.55,162 However, common to other RUNX1 functions, the
effect of RUNX1 on inflammation appears context dependent, as in
some settings RUNX1 appears pro-inflammatory in its action. For exam-
ple, in myometrial cells silencing of Runx1 with siRNA led to reduced up-
regulation of IL-1b, IL-6, and the adhesion molecules VCAM1 and
ICAM1 mRNA in response to treatment with TNF-a.164 Similarly, in
mouse peritoneal macrophages cultured in vitro the C-terminus of
RUNX1 interacts with the p50 subunit of NF-jB to co-transcriptionally
activate the production of IL-6 in response to stimulation with LPS.165
The findings that RUNX1 can act as both a positive and negative regula-
tor of NF-jB signalling is particularly intriguing, as NF-jB is a major or-
chestrator of the inflammatory actions of cytokines in heart disease.166
Importantly, NF-jB has been identified as both a cardioprotective medi-
ator and an active participant in the progression of cardiac disease
depending on the spatial-temporal resolution of its activation.166,167
Therefore, any factor capable of modulating its activity or directing its
transcriptional profile in either a positive or negative manner may be
expected to influence the outcomes of cardiac pathology.
Like the other non-myocyte cell types resident in the heart, endothe-
lial cells are gaining increasing attention for playing an active role in cardi-
omyocyte function and disease progression.168–170 Whilst a
comprehensive review of the functions of RUNX1 in endothelial cells is
beyond the scope of this review, the link between RUNX1 and angio-
genesis will be considered further due to the significance of angiogenesis
in tissue salvage post-MI and in cardiac remodelling.171 The importance
of RUNX1 in the developing vasculature is highlighted by the phenotype
of Runx1-deficient embryos which exhibit defective vascular formation
and suffer fatal haemorrhages in the CNS, pericardium, and perito-
neum.9,37 Generally, RUNX1 has a pro-angiogenic effect on endothelial
cells. In endothelial precursor cells derived from mouse embryos,
RUNX1 was shown to direct angiogenesis by inducing endothelial cell
differentiation and vascular network formation through the induction of
VE-cadherin and repression of the anti-angiogenic factor insulin-like
growth factor-binding protein 3.172 Similarly, siRNA knockdown of
Runx1 in cultured human retinal microvasculature endothelial cells
(HRMECs) decreased endothelial migration and proliferation.173 In en-
dothelial tube formation assays, an in vitro methodology used to study
the angiogenic capacity of cultured cells, treatment of HRMECs with the
RUNX1 inhibitor Ro5-3335 was associated with reduced tubular struc-
ture formation, indicating depressed angiogenic function.173 Interestingly,
in another study also using tube forming assays, treatment of human um-
bilical vein endothelial cells (HUVECs) with conditioned media prepared
from RUNX1-silenced glioblastoma cells was able to have a similar sup-
pressive effect on angiogenesis.77 This suggests that RUNX1 expression
in non-vascular cell types may be able to direct endothelial function and
angiogenic capacity via the release of paracrine signals.
Paradoxically, RUNX1 has been shown to both directly and indirectly
limit the expression of the potent pro-angiogenic factor VEGF.98,174,175
This would suggest that RUNX1 may limit angiogenesis in some circum-
stances, and in support, silencing of RUNX1 in acute myeloid leukaemia
cells increased VEGFA promoter activity and conditioned media from
these cells led to a significant improvement in the in vitro angiogenic ca-
pacity of HUVECs.175 Like its other functions, it may be that RUNX1
acts in a context-dependent manner and possess the capacity to both
stimulate or restrain angiogenic potential depending on the cellular
milieu.
In the injured heart, expansion of the vascular network through angio-
genesis is a key response which protects against adverse remodelling and
progression to heart failure.176,177 In view of the evidence linking
RUNX1 to angiogenesis, it may be valuable to explore whether the up-
regulation of RUNX1 in cardiomyocytes or in non-myocytes in the bor-
der zone following MI influences angiogenesis within this region.
12. RUNX1 as a novel target in
heart disease
Heart failure remains a major global health and economic burden.178
There is a persistent unmet need for better treatments as patients with
heart failure with reduced ejection fraction continue to have poor long-
term outcomes. Importantly, there appears to be a lack of translation be-
tween basic science discovery and drug development with most thera-
pies failing phase III clinical trials despite promising phase II testing.179
Critically, there are currently no approved treatments for heart failure
patients with preserved ejection fraction, although phase III trials are on-
going (Novartis PARAGON-HF trial and AstraZeneca DETERMINE
trial).180
Novel therapies aimed at targeting a master-regulator transcription
factor such as RUNX1 may achieve a more efficacious therapeutic re-
sponse by impacting on multiple downstream signalling pathways to miti-
gate the adverse cardiac remodelling that initiates heart failure. Given its
involvement in systolic dysfunction46 inflammation,164,165 fibrosis and
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angiogenesis,172,173 RUNX1 has been highlighted as an attractive thera-
peutic target.
Transcription factors have historically been viewed as unlikely and chal-
lenging ‘druggable’ targets due to their pleiotropic actions in multiple cell
types and systems during normal development and disease.181 More re-
cently and thanks to advances in our knowledge of transcription factor struc-
ture and function, transcription factor drivers of cancer have been directly
targeted using small molecule protein–protein interaction inhibitors.182
Importantly, the small molecule benzodiazepine Ro5-3335 was identi-
fied as a disruptor of the CBFb–RUNX interaction.129 Ro5-3335 was
shown to repress CBFb/RUNX-dependent transactivation in reporter
assays and repress RUNX1-dependent haematopoiesis in zebrafish by al-
tering the conformation of the CBFb–RUNX1 complex. Subsequently,
Ro5-3335 has been used to inhibit RUNX1 during a variety of patho-
physiological processes including, but not exclusively in, macrophages
during septic shock,165 in retinal angiogenesis173 and, acute myeloid leu-
kaemia.183 However, direct binding of Ro5-3335 to CBFb or RUNX has
not been well documented, thus whether Ro5-3335 is a direct inhibitor
of Runx remains contentious.184
Illendula et al.184 developed a selective small-molecule inhibitor of
RUNX activity. Further optimization of this compound led to a new
small-molecule inhibitor, AI-14-91, which binds selectively to CBFb and
prevents it from binding RUNX proteins via an allosteric mechanism.185
AI-14-91 has been optimized and shown to inhibit RUNX1 function in
leukaemia and basal-like breast cancer cells.185 As mentioned, adverse
cardiac remodelling is a complex response to injury involving cardiomyo-
cyte loss, hypertrophy, fibrosis, extracellular matrix remodelling, and an-
giogenesis. As RUNX1 has the potential to impact all these processes, it
is pertinent to determine whether AI-14-91 can prevent adverse remod-
elling and progression to heart failure following cardiac injury and is the
focus of on-going studies.
13. Conclusions
Accumulating evidence supports that RUNX1 is up-regulated at early
time points in the heart in response to a range of cardiac pathologies.
New developments in the field have demonstrated that RUNX1 activa-
tion in cardiomyocytes after MI is detrimental to systolic function and
cardiac structure and have thus unveiled RUNX1 as an attractive novel
target to mitigate adverse cardiac remodelling. Understanding of the role
of RUNX1 in the heart is in its infancy and there are many pertinent
questions to be asked about the identity of the downstream targets of
RUNX1 in the heart. Crossing discipline boundaries to understand
RUNX1 biology across different organs has offered insight into the po-
tential functions of RUNX1, however, due to the strong context-depen-
dent nature of RUNX1 further work is now needed to evaluate whether
the effects of RUNX1 observed in other tissues translate into the cardiac
context. This exploration should extend beyond cardiomyocytes to
study the role of RUNX1 in other cardiac cell types in heart physiology
and pathology. As a master transcription factor, RUNX1 has the poten-
tial to act across an entire network of signalling pathways. Unravelling
the functional consequences of this network represents an exciting chal-
lenge with a translational potential.
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